Analysts predict the market could reach $4 billion or more depending on how the drugs are priced. In the latest trials, the companies tested their drugs against placebo, rather than against each other or current migraine treatments, and looked at slightly different measurements of effectiveness and in different kinds of migraine patients. The improvement in migraine days for subjects getting fremanezumab exceeded the improvement seen in patients on placebo by two days, though the placebo patients also saw a benefit, according to the researchers. Patients had a mean of 1.4 or 1.9 fewer migraine days, depending on the dose taken, compared with subjects getting a placebo, who also saw an improvement. He said the new drugs would be a welcome addition to the arsenal of migraine treatments, especially for patients who don’t always remember take daily pills.

Source: Wall Street Journal November 29, 2017 22:30 UTC